Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Phase 2/3 Study to Investigate Safety and Efficacy of Brepocitinib in Adults w Lichen Planopilaris

Dermatology
Michelle Min
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris
Skin - Dermatologic

Study Description

Eligibility

  1. Age greater than or equal to 18 years
  2. Scalp biopsy consistent with LPP
  3. Active and symptomatic LPP at screening and baseline-
  4. Weight greater than 40 kg to less than 130 kg with BMI less than or equal to 45 kg/m2
  1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
  2. High risk of thrombosis or cardiovascular disease
  3. High risk of herpes zoster
  4. Active or recent infection
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.